Osawa Taro, Yamada Daisuke, Takao Tomoko, Ming Lu, Takarada Takeshi
Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
In Vitro Cell Dev Biol Anim. 2024 Dec;60(10):1132-1137. doi: 10.1007/s11626-024-00911-5. Epub 2024 Apr 25.
Mesenchymal stem cells (MSCs) have been demonstrated to be efficacious in clinical applications for the amelioration of immune disorders, including graft-versus-host disease (GvHD) and Crohn's disease. The immunosuppressive role of Programmed death-ligand 1 (PD-L1) in MSCs is pivotal, yet the regulatory mechanisms governing its expression remain to be fully elucidated. In this study, we explored the influence of paired-related homeobox (PRRX1), a determinant of multipotency and self-renewal in MSCs, on the expression of various surface antigens, notably PD-L1. Multiple isoforms of PRRX1 were found to augment the mRNA levels of MSC markers, such as CD26 and CD317, with all isoforms elevating PD-L1 expression at both mRNA and protein levels. This study reveals that PRRX1 may act as a potential immunomodulatory factor in MSCs by regulating the PD-L1 pathway.
间充质干细胞(MSCs)已被证明在改善免疫紊乱的临床应用中有效,包括移植物抗宿主病(GvHD)和克罗恩病。程序性死亡配体1(PD-L1)在MSCs中的免疫抑制作用至关重要,但其表达的调控机制仍有待充分阐明。在本研究中,我们探讨了配对相关同源框(PRRX1),一种MSCs多能性和自我更新的决定因素,对各种表面抗原表达的影响,特别是对PD-L1的影响。发现PRRX1的多种亚型可增加MSCs标志物(如CD26和CD317)的mRNA水平,所有亚型均在mRNA和蛋白质水平上提高PD-L1的表达。本研究表明,PRRX1可能通过调节PD-L1途径,在MSCs中作为一种潜在的免疫调节因子发挥作用。